Hanif 2011.
Study characteristics | |||
Patient Sampling | Cross‐sectional, consecutive, prospective | ||
Patient characteristics and setting | Presenting signs and symptoms: patients with suspicion of TB due to symptoms such as fever, cough or weight loss or both, or because they were not responding to initial therapy for other diseases Age: range 20 to 57 years Sex, female: 39% Children: no HIV infection: no Clinical setting: national reference laboratory Past history of TB: not reported Patients on anti‐TB treatment: not reported Number of specimens evaluated: 29 Laboratory level: central Country: Kuwait World Bank Income Classification: middle income High TB burden: no High TB/HIV burden: no High MDR‐TB burden: no |
||
Index tests | Xpert MTB/RIF WHO SOP or manufacturer's protocol: yes for lymph node aspirate, pleural fluid, and urine; no for CSF Manufacturer's involvement: no |
||
Target condition and reference standard(s) | Target condition: TB meningitis, lymph node TB, pleural TB, genitourinary TB Reference standard for TB detection: LJ and MGIT Reference standard for rifampicin resistance: LJ‐DST and MGIT‐DST Speciation: yes Decontamination: no |
||
Flow and timing | |||
Comparative | |||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Could the selection of patients have introduced bias? | Low risk | ||
Are there concerns that the included patients and setting do not match the review question? | Unclear | ||
DOMAIN 2: Index Test (Xpert MTB/RIF) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | Low risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Low concern | ||
DOMAIN 2: Index Test (Xpert Ultra) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | No | ||
For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? | Yes | ||
Could the reference standard, its conduct, or its interpretation have introduced bias? | High risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | Low concern | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all patients receive the same reference standard? | Yes | ||
Were all patients included in the analysis? | Yes | ||
Could the patient flow have introduced bias? | Low risk |